Guidelines for determination of the number of prior lines of therapy in multiple myeloma

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Related collections

Most cited references 2

Record: found
Abstract: found
Article: not found

Current strategies for treatment of relapsed/refractory multiple myeloma.

Jacob Laubach, Peter M. Voorhees, Hani Hassoun … (2014)

In spite of significant advances in the management of multiple myeloma (MM), the disease remains incurable and nearly all patients ultimately relapse and require salvage chemotherapy. As such, relapsed and relapsed-refractory MM remains a critical area of research pertaining to biological mechanisms of progression and chemotherapy resistance, as well as to the development of new pharmacologic agents and immunologic approaches for the disease. The immunomodulatory agents and proteasome inhibitors represent the cornerstone of treatment in this setting, with combination regimens incorporating these drugs demonstrating encouraging rates and duration of response, including the newer agents, pomalidomide and carfilzomib. In addition, novel drug classes have shown promising activity in RR MM, including the orally-administered proteasome inhibitors ixazomib and oprozomib; monoclonal antibodies such as the anti-CS1 monoclonal antibody elotuzumab and anti-CD38 monoclonal antibody daratumumab; and histone deacetylase inhibitors such as panobinostat and rocilinostat.

0 comments Cited 24 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Future agents and treatment directions in multiple myeloma.

Enrique M. Ocio, Constantine Mitsiades, Robert Orlowski … (2014)

The development of bortezomib and immunomodulatory agents resulted in a revolution in the treatment of multiple myeloma (MM). Moreover, second-generation proteasome inhibitors (carfilzomib) and immunomodulatory agents (pomalidomide) have recently been approved. Nevertheless, the incurability of this disease requires other drugs with different mechanisms of action to either prolong the survival of patients refractory to current therapies, or achieve cure. Active research has been done exploring the pathogenesis of MM and searching for novel, druggable targets. In this regard, some of these novel agents seem promising, such as monoclonal antibodies (anti-CD38 - daratumumab or anti-CS1 - elotuzumab) or the kinesin protein inhibitor Arry-520. Other agents under investigation are kinase inhibitors, signaling pathways inhibitors or deacetylase inhibitors. With so many novel agents under investigation, future therapy in MM will probably involve the combined use of the already approved drugs with some of those newly discovered.

0 comments Cited 8 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Journal

Title: Blood

Abbreviated Title: Blood

Publisher: American Society of Hematology

ISSN (Print): 0006-4971

ISSN (Electronic): 1528-0020

Publication date Created: August 13 2015

Publication date (Print): August 13 2015

Volume: 126

Issue: 7

Pages: 921-922

Article

DOI: 10.1182/blood-2015-05-647636

PubMed ID: 26272048

SO-VID: f9a01bbe-f6d7-4d0e-bc89-2ff9009894f6

History

Data availability:

Comments

Comment on this article

scite_

Cited by 33

See all cited by

Most referenced authors 207

See all reference authors